Our previous molecular analyses within the POETIC trial have identified the baseline HER2-E subtype as a statistically significant predictor of resistance to aromatase inhibitors in ER+/HER2+ BC that is also associated with an increased risk of relapse relative to Luminal tumours. This evidence concerns the gene ESR1 and neoplasm.